Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation

被引:14
|
作者
Fontova, Pere [1 ,2 ,3 ]
Colom, Helena [4 ]
Rigo-Bonnin, Raul [2 ,5 ]
van Merendonk, Lisanne N. [1 ,2 ,3 ]
Vidal-Alabro, Anna [1 ,2 ,3 ]
Montero, Nuria [1 ,2 ,3 ]
Melilli, Edoardo [1 ,2 ,3 ]
Meneghini, Maria [1 ,2 ,3 ]
Manonelles, Anna [1 ,2 ,3 ]
Cruzado, Josep M. [1 ,2 ,3 ]
Torras, Juan [1 ,2 ,3 ]
Grinyo, Josep Maria [1 ,2 ,3 ]
Bestard, Oriol [1 ,2 ,3 ]
Lloberas, Nuria [1 ,2 ,3 ]
机构
[1] Bellvitge Univ Hosp, Nephrol Dept, Barcelona, Spain
[2] Inst Invest Biomed Bellvitge, Nephrol & Transplantat, Barcelona, Spain
[3] Univ Barcelona, Dept Clin Sci, Barcelona, Spain
[4] Univ Barcelona, Sch Pharm, Dept Pharm & Pharmaceut Technol, Biopharmaceut & Pharmacokinet Unit, Barcelona, Spain
[5] Univ Bellvitge, Bellvitge Univ Hosp, Biochem Dept, Inst Invest Biomed Bellvitge, Barcelona, Spain
关键词
tacrolimus; pharmacodynamic; pharmacokinetics; circadian rhythm; kidney transplantation; immunosuppression; BLOOD MONONUCLEAR-CELLS; MULTIDRUG-RESISTANCE GENE; CYCLOSPORINE; LIVER; METABOLISM; ABSORPTION; CHRONOPHARMACOKINETICS; PHARMACOGENETICS; POLYMORPHISMS; EXPRESSION;
D O I
10.3389/fphar.2021.636048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Tacrolimus is the backbone immunosuppressant after solid organ transplantation. Tacrolimus has a narrow therapeutic window with large intra- and inter-patient pharmacokinetic variability leading to frequent over- and under-immunosuppression. While routine therapeutic drug monitoring (TDM) remains the standard of care, tacrolimus pharmacokinetic variability may be influenced by circadian rhythms. Our aim was to analyze tacrolimus pharmacokinetic/pharmacodynamic profiles on circadian rhythms comparing morning and night doses of a twice-daily tacrolimus formulation. Methods: This is a post-hoc analysis from a clinical trial to study the area under curve (AUC) and the area under effect (AUE) profiles of calcineurin inhibition after tacrolimus administration in twenty-five renal transplant patients. Over a period of 24 h, an intensive sampling (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20, and 24 h) was carried out. Whole blood and intracellular tacrolimus concentrations and calcineurin activity were measured by UHPLC-MS/MS. Results: Whole blood and intracellular AUC(12-24 h) and C-max achieved after tacrolimus night dose was significantly lower than after morning dose administration (AUC(0-12 h)) (p < 0.001 for both compartments). AUE(0-12 h) and AUE(12-24 h) were not statistically different after morning and night doses. Total tacrolimus daily exposure (AUC(0-24 h)), in whole blood and intracellular compartments, was over-estimated when assessed by doubling the morning AUC(0-12 h) data. Conclusion: The lower whole blood and intracellular tacrolimus concentrations after night dose might be influenced by a distinct circadian clock. This significantly lower tacrolimus exposure after night dose was not translated into a significant reduction of the pharmacodynamic effect. Our study may provide conceptual bases for better understanding the TDM of twice-daily tacrolimus formulation.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
    Yu, Meng
    Liu, Mouze
    Zhang, Wei
    Ming, Yingzi
    CURRENT DRUG METABOLISM, 2018, 19 (06) : 513 - 522
  • [2] Tacrolimus pharmacokinetics after kidney transplantation - Influence of changes in haematocrit and steroid dose
    Staatz, Christine E.
    Storset, Elisabet
    Bergmann, Troels K.
    Hennig, Stefanie
    Holford, Nick
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (06) : 1475 - 1476
  • [3] Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation
    Saeves, Ingjerd
    Line, Pal-Dag
    Bremer, Sara
    Vethe, Nils T.
    Tveit, Ragnhild G.
    Meltevik, Tore J.
    Bergan, Stein
    THERAPEUTIC DRUG MONITORING, 2014, 36 (01) : 46 - 53
  • [4] Tacrolimus Pharmacokinetics in Hispanic Children After Kidney Transplantation
    Cherala, G.
    Munar, M. Y.
    Naher, A.
    Al-Uzri, A.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (10) : 3708 - 3712
  • [5] Response to 'Tacrolimus pharmacokinetics after kidney transplantation - Influence of changes in haematocrit and steroid dose'
    Vanhove, Thomas
    de Jonge, Hylke
    de Loor, Henriette
    Verbeke, Kristin
    Kuypers, Dirk R. J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (06) : 1473 - 1474
  • [6] Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
    Staatz, CE
    Tett, SE
    CLINICAL PHARMACOKINETICS, 2004, 43 (10) : 623 - 653
  • [7] Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
    Christine E. Staatz
    Susan E. Tett
    Clinical Pharmacokinetics, 2004, 43 : 623 - 653
  • [8] Pharmacodynamics and population pharmacokinetics of tacrolimus in Chinese kidney transplant recipients
    Janicki, Piotr K.
    Kadry, Zakiyah
    PHARMACOGENOMICS, 2013, 14 (07) : 719 - 719
  • [9] Tacrolimus pharmacokinetics and pharmacodynamics in kidney transplantation: The role of CYP3A5 polymorphism in a pediatric population
    Ghio, L.
    Ferraresso, M.
    Tirelli, S.
    Grillo, P.
    Belingheri, M.
    Martina, V.
    Torresani, E.
    Edefonti, A.
    PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1588 - 1588
  • [10] Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients
    Ferraresso, Mariano
    Tirelli, Amedea
    Ghio, Luciana
    Grillo, Paolo
    Martina, Valentina
    Torresani, Erminio
    Edefonti, Alberto
    PEDIATRIC TRANSPLANTATION, 2007, 11 (03) : 296 - 300